Jenburkt Pharmaceuticals (BOM:524731) Beta: 1.0463 (As of Jul. 01, 2026)


BOM:524731 Jenburkt Pharmaceuticals Ltd BOM:524731
82 GF Score
Price ₹1,109.65
GF Value ₹1,111.70
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Jenburkt Pharmaceuticals Beta?

Jenburkt Pharmaceuticals BOM:524731 -1.47% 82 Beta is 1.0463 as of Jul. 01, 2026. GuruFocus rates BOM:524731 with a GF Score™ of 82/100 and a GF Value™ of ₹1,111.70 (Fairly Valued). The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-01), Jenburkt Pharmaceuticals's Beta is 1.0463.


Jenburkt Pharmaceuticals  (BOM:524731) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Jenburkt Pharmaceuticals Beta Related Terms


Jenburkt Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Jenburkt Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jenburkt Pharmaceuticals Beta Chart

Jenburkt Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.96 1.09 1.22 1.13

Jenburkt Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.22 1.17 1.24 1.36 1.13

BOM:524731 vs ZTS, UTHR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jenburkt Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jenburkt Pharmaceuticals Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jenburkt Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Jenburkt Pharmaceuticals's Beta falls into.


BOM:524731
82GF Score
Jenburkt Pharmaceuticals Ltd BOM:524731
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jenburkt Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.0463 mean?
Jenburkt Pharmaceuticals (BOM:524731) has a Beta of 1.0463 as of Jul. 01, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Jenburkt Pharmaceuticals and its competitors.
Is Jenburkt Pharmaceuticals' Beta too high?
Jenburkt Pharmaceuticals' current Beta is 1.0463. Overall, Jenburkt Pharmaceuticals has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jenburkt Pharmaceuticals' Beta compare to ZTS and UTHR?
Jenburkt Pharmaceuticals' Beta of 1.0463 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Jenburkt Pharmaceuticals and its competitors. Jenburkt Pharmaceuticals's current Beta is 1.0463. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenburkt Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals (BOM:524731) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,111.70, compared to a current price of ₹1,109.65 — trading 0.2% below its estimated fair value. The current Beta is 1.0463. Jenburkt Pharmaceuticals' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Jenburkt Pharmaceuticals (BOM:524731), the current Beta is 1.0463 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jenburkt Pharmaceuticals (BOM:524731) Overvalued in 2026?

Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be undervalued. The current stock price of ₹1,109.65 is trading 0.2% below its estimated GF Value™ of ₹1,111.70. GuruFocus considers Jenburkt Pharmaceuticals to be Fairly Valued.

Key valuation signals for BOM:524731:

  • Beta: 1.0463
  • GF Value™: ₹1,111.70 vs. price of ₹1,109.65 (0.2% below fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the BOM:524731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jenburkt Pharmaceuticals Business Description

Address 93, Jayprakash Road, Nirmala Apartments, Andheri (West, Mumbai, MH, IND, 400058
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
82GF Score

Get the complete analysis for BOM:524731

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,109.65
Price
₹1,111.70
GF Value